These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 35414304)
1. Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population. Rana KB; Britnell SR; Gilbertson ME; Ibrahim SL J Pharm Pract; 2023 Oct; 36(5):1095-1101. PubMed ID: 35414304 [No Abstract] [Full Text] [Related]
2. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622 [TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population. Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221 [TBL] [Abstract][Full Text] [Related]
5. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes. Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449 [TBL] [Abstract][Full Text] [Related]
6. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Johansen P; Sandberg A; Capehorn M Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148 [TBL] [Abstract][Full Text] [Related]
7. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL; Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288 [TBL] [Abstract][Full Text] [Related]
8. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States. Cui J; Klepser DG; McAdam-Marx C J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562 [No Abstract] [Full Text] [Related]
9. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244 [No Abstract] [Full Text] [Related]
10. The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes. Meyer J; Dreischmeier E; Lehmann M; Phelan J Ann Pharmacother; 2023 Mar; 57(3):241-250. PubMed ID: 35778801 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305 [TBL] [Abstract][Full Text] [Related]
12. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Lane W; Weinrib S; Rappaport J Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Pinelli NR; Hurren KM Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278 [TBL] [Abstract][Full Text] [Related]
15. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study). Takahashi Y; Nomoto H; Yokoyama H; Takano Y; Nagai S; Tsuzuki A; Cho KY; Miya A; Kameda H; Takeuchi J; Taneda S; Kurihara Y; Atsumi T; Nakamura A; Miyoshi H; Diabetes Obes Metab; 2023 Jun; 25(6):1503-1511. PubMed ID: 36722623 [TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect? Li Y; Rosenblit PD Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238 [TBL] [Abstract][Full Text] [Related]
17. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ; Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120 [TBL] [Abstract][Full Text] [Related]
18. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT; JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037 [TBL] [Abstract][Full Text] [Related]
19. Is insulin the most effective injectable antihyperglycaemic therapy? Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312 [TBL] [Abstract][Full Text] [Related]
20. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. Tuchscherer RM; Thompson AM; Trujillo JM Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]